HC Wainwright Reaffirms Buy Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

HC Wainwright reaffirmed their buy rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a $11.00 price target on the stock.

CRVS has been the topic of several other reports. StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, Oppenheimer raised their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Corvus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Stock Down 3.9 %

CRVS stock opened at $4.73 on Tuesday. The company has a market cap of $303.95 million, a price-to-earnings ratio of -5.09 and a beta of 1.07. The business has a fifty day simple moving average of $7.04 and a 200-day simple moving average of $5.51. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Samlyn Capital LLC increased its stake in Corvus Pharmaceuticals by 160.7% during the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after buying an additional 3,774,658 shares during the period. Marshall Wace LLP purchased a new stake in shares of Corvus Pharmaceuticals during the second quarter worth about $136,000. Cubist Systematic Strategies LLC acquired a new position in shares of Corvus Pharmaceuticals in the second quarter worth about $44,000. Point72 Asset Management L.P. acquired a new position in shares of Corvus Pharmaceuticals in the second quarter worth about $10,855,000. Finally, Avity Investment Management Inc. boosted its holdings in Corvus Pharmaceuticals by 138.2% in the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock valued at $146,000 after purchasing an additional 16,000 shares during the last quarter. 46.64% of the stock is owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.